MTP51

MTP51 is an investigational medical device filler developed by Medytox, a South Korean biopharmaceutical company specializing in aesthetic products. Currently in the discovery phase, MTP51 is specifically designed for the correction of fine lines. As a dermal filler, it is intended to be injected into the skin to provide physical volumization, thereby smoothing out superficial wrinkles and improving skin texture. While Medytox's established filler portfolio, such as the Neuramis line, typically utilizes cross-linked hyaluronic acid (HA) produced via their proprietary SHAPE technology, MTP51 represents a next-generation candidate in their research pipeline aimed at expanding their aesthetic treatment options for subtle skin corrections.